Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,985 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Carcinoma of Head/Neck Clear all
Completed Phase 2 Interventional Results available

Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT00084682
View directory record Official record
Conditions
Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions
romidepsin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 24, 2026, 1:22 PM EDT
Active, not recruiting Phase 1 Interventional

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

NCT01947023
View directory record Official record
Conditions
Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Dabrafenib, Dabrafenib Mesylate, Echocardiography Test, Lapatinib, Lapatinib Ditosylate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 24, 2026, 1:22 PM EDT
Terminated Phase 1 Interventional

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

NCT03809624
View directory record Official record
Conditions
Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Interventions
INBRX-105 - PDL1x41BB antibody, Pembrolizumab
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
23
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 3 Interventional

Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery

NCT00002670
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
chemotherapy, cisplatin, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2013
U.S. locations
22
States / cities
Tampa, Florida • Atlanta, Georgia • Decatur, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 1 Interventional

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

NCT01413113
View directory record Official record
Conditions
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer
Interventions
pazopanib hydrochloride, iodine I 131
Drug · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 1Phase 2 Interventional

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT04815720
View directory record Official record
Conditions
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Interventions
pepinemab + pembrolizumab
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Springdale, Arkansas • Fresno, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 24, 2026, 1:22 PM EDT
Active, not recruiting Early Phase 1 Interventional Results available

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

NCT05245682
View directory record Official record
Conditions
Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasopharyngeal Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Interventions
Tolinapant, Radiation Therapy
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 24, 2026, 1:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

NCT04787042
View directory record Official record
Conditions
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions
ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
Biological
Lead sponsor
Simcha IL-18, Inc.
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 24, 2026, 1:22 PM EDT
Not yet recruiting Phase 2 Interventional

Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial

NCT07783581
View directory record Official record
Conditions
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Photon Stereotactic Body Radiation Therapy, Positron Emission Tomography, Spatially-fractionated Radiation Therapy, Surgical Procedure
Procedure · Biological · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 1 Interventional

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

NCT04091867
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
sEphB4-HSA with chemotherapy, Cetuximab, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 24, 2026, 1:22 PM EDT
Withdrawn Phase 2 Interventional

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT05359692
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
INCAGN01876, retifanlimab
Biological
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 1 Interventional

Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00114153
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
capecitabine, carboplatin, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 2 Interventional

Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

NCT00077428
View directory record Official record
Conditions
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Adenoid Cystic Carcinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer
Interventions
bortezomib, doxorubicin hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 24, 2026, 1:22 PM EDT
Completed No phase listed Observational

Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck

NCT00002695
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
DNA stability analysis, microsatellite instability analysis, mutation analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 120 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 1 Interventional

Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer

NCT04572100
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
Transoral Robotic Surgery (TORS) or Radiotherapy, Chemotherapy and Low-Dose Radiotherapy, Chemotherapy and High-Dose Radiotherapy, Paclitaxel, Carboplatin
Other · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Not applicable Interventional

Positron Emission Tomography in Determining Stage of Esophageal Cancer

NCT00004867
View directory record Official record
Conditions
Esophageal Cancer
Interventions
conventional surgery, positron emission tomography, radionuclide imaging, fludeoxyglucose F 18, chemotherapy, Radiotherapy
Procedure · Radiation · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 24, 2026, 1:22 PM EDT
Terminated Not applicable Interventional

Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule

NCT05003856
View directory record Official record
Conditions
Benign Thyroid Gland Neoplasm, Recurrent Thyroid Gland Carcinoma, Thyroid Gland Follicular Tumor of Uncertain Malignant Potential, Thyroid Gland Nodule, Thyroid Gland Papillary Carcinoma
Interventions
Quality-of-Life Assessment, Radiofrequency Ablation
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 24, 2026, 1:22 PM EDT
Terminated Phase 3 Interventional

Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma

NCT00198328
View directory record Official record
Conditions
Head Neck Cancer
Interventions
Medpulser Electroporation with Bleomycin, Surgical Excision
Combination Product · Procedure
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT04196283
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-368, Tilsotolimod, Nab-paclitaxel, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Chicago, Illinois • Louisville, Kentucky • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer

NCT02830594
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Squamous Cell Carcinoma AJCC v7
Interventions
External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
Radiation · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

NCT00389441
View directory record Official record
Conditions
Thyroid Neoplasms
Interventions
AG-013736
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
10
States / cities
Orange, California • Aurora, Colorado • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 24, 2026, 1:22 PM EDT
Terminated Phase 2 Interventional Results available

Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

NCT02068157
View directory record Official record
Conditions
Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
Interventions
Laboratory Biomarker Analysis, Photodynamic Therapy, Porfimer Sodium
Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 24, 2026, 1:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

NCT07030257
View directory record Official record
Conditions
Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic
Interventions
CP-383
Drug
Lead sponsor
Tasca Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 24, 2026, 1:22 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205
View directory record Official record
Conditions
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
BNT113, Pembrolizumab
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 24, 2026, 1:22 PM EDT